Leading HIV researchers announced important new developments in HIV research at the 23rd International AIDS Conference (AIDS 2020: Virtual) held recently. This includes what may be the first report of an adult with HIV to achieve long-term HIV remission without the need for a bone marrow transplant and new data showing that long-acting injectable cabotegravir is superior to daily oral Truvada for pre-exposure prophylaxis (PrEP).
Other announcements included promising new insights on PrEP's impact on reducing HIV incidence in rural Kenya and Uganda, encouraging data on the potential link between dolutegravir and neural tube defects, and positive results in a trial comparing multidrug antiretroviral therapies.
"Since 1985 the International AIDS Conference has helped answer the most pressing research questions in HIV, and this year is no different," Anton Pozniak, President of the International AIDS Society and International Chair of AIDS 2020: Virtual, said. "The studies presented at AIDS 2020: Virtual advance our knowledge on multiple fronts, knowledge that can potentially help the communities and regions most impacted by HIV worldwide."